s membrane disorder, back pain, infection,
headache, nausea, stomatitis (mouth sores), vomiting, constipation,
diarrhea, anorexia, dyspepsia (indigestion), intestinal
obstruction, peripheral edema (foot, leg, and/or ankle swelling),
paresthesia (sensation of tingling, pricking, or numbness of the
skin), pharyngitis (sore throat), dyspnea (shortness of breath),
hand-foot syndrome (a skin irritation, typically occurring on the
hands and feet), rash, and alopecia (hair loss).
About Schering-Plough
Schering-Plough Corporation is a global science-based health
care company with leading prescription, consumer and animal health
products. Through internal research and collaborations with
partners, Schering-Plough discovers, develops, manufactures and
markets advanced
drug therapies to meet important medical needs. Schering-Plough's
vision is to earn the trust of the physicians, patients and
customers served by its more than 33,500 people around the world.
The company's Web site is
www.scheringplough.com.
SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press
release
includes certain "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, including the
potential market and prospects for CAELYX. Forward-looking
statements relate to expectations or forecasts of future events.
Actual results may vary materially from the forward-looking
statements, and there are no guarantees about the performance of
Schering-Plough stock or Schering-Plough's business.
Schering-Plough does not assume the obligation to update any
forward-looking statement. Many factors could cause actual results
to differ from Schering- Plough's forward-looking statements,
including uncertainties in the regulatory process, market
acceptance of CAELYX, manufacturing issues, current and future
branded and generic competition, timing of trade buying, and
'"/>Page: 1 2 3 4 5 Related medicine technology :1.
Appendicitis: Evolving Tools to Diagnose a Classic Disease2.
Non-Invasive Diagnostic Tests for Celiac Disease3.
Corgenix Reports New Clinical Data Correlating AtherOx Technology
With Vascular Disease4.
AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease5.
Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able
to Heal From Alzheimers Disease6.
BusinessWeek Article Highlights Promising Breakthrough Treatment
for Advanced Coronary Artery Disease7.
BusinessWeek Article Highlights Promising Breakthrough Treatment
for Advanced Coronary Artery Disease8.
Lexicon Develops Antibodies That Lower Triglycerides and
Cholesterol as Potential New Therapy for Heart Disease9.
Beike Biotechnology Study Suggests Adult Stem Cells Show Promise
for Peripheral Vascular Disease10.
ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical
Model11.
Resveratrol Studies Suggest Broad Implications for SIRT1 Activation
in Neurodegenerative Diseases of Aging Such as Alzheimers Disease